Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Simon-Kucher Selects Navan to Modernize Global Travel Program24.2.2026 12:00:00 EET | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Simon-Kucher, the world’s leading commercial growth and pricing consultancy, as its global travel partner. Simon-Kucher teams will now have access to Navan’s AI-powered travel management platform across more than a dozen markets, including in the North American, European, and APAC regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224745907/en/ Simon-Kucher Selects Navan to Modernize Global Travel Program “Our work is increasingly global, and travel remains essential to how we collaborate with clients and with one another,” said Thomas Wohlan, Director of Travel Management at Simon-Kucher. “To support that at scale, we needed a modern travel platform that brings consistency across countries and simplifies the experience for our teams. Navan enables us to operate more efficiently on a single global
Khazna Awarded Uptime Tier III Certification of Design Documents for Ajman, UAE Facility, Largest in Company’s Portfolio24.2.2026 11:00:00 EET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, today announced that Khazna Data Centers, a global leader in hyperscale digital infrastructure, has achieved the Uptime Institute Tier III Certification of Design Documents (TCDD) award for its newest 100 MW AI-optimized data center, QAJ01 —set to be the first certified AI data center with liquid cooling in the Middle East and North Africa region. Representing the largest facility in Khazna’s portfolio, this state-of-the-art development features 20 data halls, each delivering 5 MW of IT capacity, purpose-built to meet the demands of next-generation artificial intelligence (AI) workloads. The certification underscores Khazna’s commitment to designing world-class, resilient, and efficient data center infrastructure in alignment with the industry’s most rigorous global standards. Located in Ajman, United Arab Emirates, the new facility has been designed with advanced liquid-cooling systems to support the high rack densities an
Infobip and ESA Boost Asteroid Impact Alerts with Instant Voice Calls24.2.2026 11:00:00 EET | Press release
Global cloud communications platform, Infobip, has partnered with the European Space Agency (ESA) to improve the delivery of asteroid impact alerts via Infobip's Voice API solutions. Using Infobip’s platform, ESA personnelnow receive instant voice calls, enabling faster, 24/7 alerts for potential asteroid impacts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224294384/en/ European Space Agency partners with Infobip for asteroid impact alerts. Understanding the trajectories of asteroids, particularly those approaching Earth, known as near-Earth objects (NEOs), is crucial and time sensitive. As single asteroid impact 65 million years ago wiped out most life on Earth, it is vital for the ESA to identify all hazardous asteroids to better understand their physical characteristics and the potential consequences of an impact. Previously, ESA personnel were notified via email, often when they were offline and unavailable. By in
ElevenEs held 1st Closing of its Series B Investment Round Backed by Caterpillar Venture Capital Inc.24.2.2026 10:24:00 EET | Press release
ElevenEs has completed the first closing of its Series B investment round, backed by Caterpillar Venture Capital Inc., a wholly owned subsidiary of Caterpillar Inc. (NYSE: CAT) - the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Additionally, an affiliate of BST (HK) Ltd., a leading Hong Kong-based commodity trading house, participated in the round. This transaction represents a significant milestone in the future of European battery manufacturing as the proceeds will be used for the initial phases of infrastructure and equipment toward the planned 1GWh Mega-Factory, with construction starting in February 2026. The first battery cell deliveries are expected in 2027. This project positions ElevenEs at the forefront of the global energy transition and marks a significant step forward in delivering advanced electrified solutions from European sources. ElevenEs is scali
Thredd Powers MuchBetter's Expansion into Israel, Supporting Global Growth Strategy24.2.2026 10:00:00 EET | Press release
Thredd, the AI-first issuer processing platform, today announced the expansion of their partnership with MuchBetter, the consumer wallet and prepaid card platform, supporting the company’s launch in Israel. This marks the latest milestone in MuchBetter’s international expansion, powered by Thredd, following the successful deployment of their programme in the UK and Canada. Through the partnership, Thredd is providing processing infrastructure for MuchBetter’s prepaid card and digital wallet programme, enabling consumers in Israel to securely load funds and make payments using physical and virtual cards, with additional form factors planned as the programme scales. “International expansion is a core part of MuchBetter’s growth strategy, and Thredd has been a critical partner in helping us move quickly and confidently into new markets,” said Israel Rosenthal, Founder and CEO of MuchBetter. “Launching in Israel is an important step for us, and Thredd’s global platform, regulatory expertis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom